普利製藥(300630.SZ):注射用蘭索拉唑獲得藥品註冊批件
格隆匯 11 月 29日丨普利製藥(300630.SZ)公佈,公司於近日獲得國家藥品監督管理局簽發的注射用蘭索拉唑的生產批件,適應症:用於口服療法不適用的伴有出血的胃、十二指腸潰瘍、急性應激潰瘍、急性胃粘膜損傷。
蘭索拉唑屬於質子泵抑制劑,其注射劑由日本武田公司研發,於2006年12月首次在日本上市,國產注射用蘭索拉唑於2010年5月獲國家藥品監督管理局批准上市。
普利製藥的注射用蘭索拉唑成功研發後,遞交了中國仿製藥註冊申請,並於近日取得國家藥品監督管理局上市許可,將對公司拓展國內市場帶來積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.